Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argenica TherapeuticsASX:AGN 25 EV-to-EBITDA is -2.17 as of Aug. 18, 2026. GuruFocus rates ASX:AGN with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 401 Biotechnology companies, Argenica Therapeutics ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Argenica Therapeutics's enterprise value is A$21.30 Mil.
Argenica Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.80 Mil. Therefore, Argenica Therapeutics's EV-to-EBITDA for today is -2.17.
The historical rank and industry rank for Argenica Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:AGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.17 Med: 0 Max: 0
Current: -2.17
ASX:AGN's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs ASX:AGN: -2.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Argenica Therapeutics's PE Ratio (TTM) for today is calculated as:
Argenica Therapeutics's share price for today is A$0.205.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argenica Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.077.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Argenica Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Argenica Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AGN vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Argenica Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argenica Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Argenica Therapeutics's EV-to-EBITDA falls into.
Argenica Therapeutics's current Enterprise Value is A$21.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argenica Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argenica Therapeutics (ASX:AGN) has a EV-to-EBITDA of -2.17 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Argenica Therapeutics. According to the industry distribution chart, Argenica Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry.
Is Argenica Therapeutics' EV-to-EBITDA too high?
Argenica Therapeutics' current EV-to-EBITDA is -2.17. Based on the distribution chart, Argenica Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Argenica Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Argenica Therapeutics ranks #999999 out of 401 companies for EV-to-EBITDA. This places Argenica Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Argenica Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argenica Therapeutics's current EV-to-EBITDA is -2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current EV-to-EBITDA of -2.17. The current EV-to-EBITDA is -2.17. Argenica Therapeutics' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current EV-to-EBITDA is -2.17 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
25GF Score
Get the complete analysis for ASX:AGN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AGN has been successfully added to your 
